01 March 2011

LCT Granted Australian Patent

In a press release, Living Cell Technologies announced it has been granted a patent by the Australian Patent Office for IMMUPEL™. This is the industry leading technology for encapsulating living cells prior to transplantation. The granting of the Australian patent provides protection of this crucial intellectual property in advance of possible future clinical trials in Australia. What country will be next?

This selectively permeable system protects encapsulated living cells from immune rejection without the need for immunnosuppressant drugs, while at the same time allowing the transplanted cells to survive and function normally.

This technology has been demonstrated in Russia and in an on-going Phase II clinical trial in New Zealand, the IMMUPEL platform, as used in LCT's DIABECELL® product, has facilitated the effective transplantation of insulin-secreting porcine pancreatic cells into diabetes patients. Russia has approved its use.

Living Cell Technologies' product is the first to show clear efficacy in humans using encapsulated cells derived from another species, in this case from pigs.

So for readers in Australia watch for clinical trials. For those that want further information and to follow press releases, bookmark this. Use the contact to request information.

No comments:

Post a Comment